- Centene Corporation (NYSE:CNC) has agreed to sell Magellan Rx to Prime Therapeutics LLC and PANTHERx Rare to a consortium of The Vistria Group, General Atlantic, and Nautic Partners.
- Centene expects to receive approximately $2.8 billion in aggregate proceeds from the transactions.
- Magellan Rx is a comprehensive pharmacy solutions organization with specialty drug management, Medicaid administration, and comprehensive pharmacy benefits management capabilities.
- Centene acquired Magellan Rx in January 2022 as part of its acquisition of Magellan Health, Inc.
- PANTHERx is a specialty pharmacy. Centene acquired PANTHERx in December 2020.
- Centene will use most of the net proceeds from the sales to repurchase stock and the balance to reduce debt.
- Each transaction is expected to be neutral to slightly accretive to Centene's Adjusted Earnings Per Share in 12 months post-closing.
- The company closed the March quarter with long-term debt of 18.64 billion.
- Price Action: CNC shares are up 0.93% at $83.67 during the market session on the last check Thursday.
